US drug maker Moderna said it will request the Food and Drug Administration (FDA) to grant emergency use authorization for its Covid-19 vaccine to inoculate children under 6 years of age.
The company will submit the request to the FDA, as well as the European Medicines Agency and other global regulators "in the coming weeks", Xinhua news agency quoted Moderna as saying in a statement on Wednesday.
The submission was based on tests of its Covid-19 vaccine, known as mRNA-1273, in children aged 6 months to under 2 years, and 2 years to under 6 years.
The interim analysis showed a robust neutralising antibody response in both age groups after a 25 microgram two-dose primary series of mRNA-1273 along with a favourable safety profile, according to the company.
In the study, vaccine efficacy in children aged 6 months to 2 years was 43.7 per cent, and 37.5 per cent in the 2 to under 6 years age group, said Moderna.
--IANS
ksk/
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)